Progyny (NASDAQ:PGNY) Price Target Lowered to $17.00 at Barclays

Progyny (NASDAQ:PGNY - Free Report) had its price target decreased by Barclays from $30.00 to $17.00 in a research note released on Thursday,Benzinga reports. Barclays currently has an overweight rating on the stock.

A number of other brokerages also recently issued reports on PGNY. Jefferies Financial Group lowered their price target on Progyny from $31.00 to $24.00 and set a "buy" rating for the company in a report on Thursday, September 19th. Leerink Partnrs downgraded shares of Progyny from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 7th. Bank of America reduced their target price on Progyny from $22.00 to $21.00 and set a "buy" rating for the company in a report on Wednesday. Canaccord Genuity Group decreased their price target on Progyny from $18.00 to $17.00 and set a "hold" rating on the stock in a research note on Wednesday. Finally, Leerink Partners decreased their target price on Progyny from $25.00 to $21.00 and set a "market perform" rating on the stock in a research report on Thursday, September 19th. Eight analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Progyny currently has a consensus rating of "Hold" and a consensus price target of $25.42.

Progyny Stock Performance

Shares of Progyny stock traded up $0.08 on Thursday, hitting $13.98. The company's stock had a trading volume of 2,231,856 shares, compared to its average volume of 1,393,735. The company has a market capitalization of $1.26 billion, a price-to-earnings ratio of 23.97, a price-to-earnings-growth ratio of 1.62 and a beta of 1.44. The firm has a fifty day moving average price of $17.69 and a 200-day moving average price of $23.56. Progyny has a 1 year low of $13.77 and a 1 year high of $42.08.

Progyny (NASDAQ:PGNY - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.37 by ($0.26). Progyny had a net margin of 5.03% and a return on equity of 10.87%. The company had revenue of $286.63 million during the quarter, compared to analyst estimates of $296.85 million. During the same period in the prior year, the business posted $0.16 EPS. Progyny's revenue was up 2.0% compared to the same quarter last year. As a group, analysts forecast that Progyny will post 0.64 EPS for the current year.

Institutional Trading of Progyny

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PGNY. Vanguard Group Inc. grew its position in Progyny by 0.5% during the first quarter. Vanguard Group Inc. now owns 8,311,840 shares of the company's stock valued at $317,097,000 after acquiring an additional 41,687 shares during the period. International Assets Investment Management LLC increased its holdings in Progyny by 1,576.0% in the third quarter. International Assets Investment Management LLC now owns 2,565,118 shares of the company's stock valued at $42,991,000 after buying an additional 2,412,068 shares during the last quarter. Pacer Advisors Inc. increased its holdings in shares of Progyny by 12,579.4% in the 3rd quarter. Pacer Advisors Inc. now owns 2,492,642 shares of the company's stock valued at $41,777,000 after acquiring an additional 2,472,983 shares during the last quarter. Farallon Capital Management LLC lifted its position in Progyny by 120.8% in the 2nd quarter. Farallon Capital Management LLC now owns 1,308,500 shares of the company's stock valued at $37,436,000 after purchasing an additional 715,900 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Progyny by 24.8% during the second quarter. Dimensional Fund Advisors LP now owns 1,281,928 shares of the company's stock valued at $36,676,000 after acquiring an additional 254,725 shares during the period. Hedge funds and other institutional investors own 94.93% of the company's stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.